4186.TWO Taiwan Advance Bio-Pharmaceutical Inc.
- Market cap
- TWD 605M
- P/E
- 39.5x
- P/B
- 2.37x
- ROE
- 9.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4186.TWO undervalued?
Graham number4186.TWO trades 104.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Taiwan Advance Bio-Pharmaceutical Inc. fundamental analysis
No fundamental analysis for Taiwan Advance Bio-Pharmaceutical Inc. yet.
Taiwan Advance Bio-Pharmaceutical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Taiwan Advance Bio-Pharmaceutical Inc.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA and rapid test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and polyclonal antibody products. It also offers stem cell banking services for newborn and ad…
Full company profileTaiwan Advance Bio-Pharmaceutical Inc. financial statements
Taiwan Advance Bio-Pharmaceutical Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 206M | 236M | 243M | 318M | 316M | 354M | 365M |
| Gross Profit | 112M | 128M | 125M | 193M | 198M | 244M | 234M |
| Operating Income | -155M | -90.7M | -103M | 7.61M | 4.27M | 44.8M | 37.4M |
| EBITDA | -138M | -39.2M | -76.7M | 38.0M | 21.8M | 50.6M | 53.4M |
| Net Income | -175M | -86.4M | -119M | 3.17M | -10.7M | 22.9M | 28.0M |
| EPS | -2.30 | -1.07 | -1.32 | 0.04 | -0.12 | 0.25 | 0.31 |
| Balance Sheet | |||||||
| Total Assets | 655M | 823M | 714M | 707M | 749M | 676M | 747M |
| Total Liabilities | 270K | 465M | 472M | 462M | 515M | 420M | 462M |
| Shareholders' Equity | 195M | 359M | 241M | 245M | 234M | 256M | 285M |
| Cash & Short-term Investments | 106M | 237M | 160M | 159M | 182M | 106M | 141M |
| Total Debt | 268M | 274M | 256M | 291M | 320M | 236M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -151M | -50.3M | -48.1M | -20.6M | 12.6M | 8.33M | 53.1M |
| Capital Expenditure | 46.5M | 55.7M | 14.2M | 7.28M | 11.9M | 3.96M | 33.4M |
| Free Cash Flow | -197M | -106M | -62.3M | -27.9M | 667K | 4.37M | 19.8M |
| Ratios | |||||||
| ROE | -89.5% | -24.1% | -49.1% | 1.3% | -4.6% | 8.9% | 9.8% |
| ROA | -26.7% | -10.5% | -16.6% | 0.4% | -1.4% | 3.4% | 3.8% |
| Net Profit Margin | -84.9% | -36.7% | -48.7% | 1.0% | -3.4% | 6.5% | 7.7% |
| Debt to Equity | 1.37x | 0.76x | 1.06x | 1.19x | 1.37x | 0.92x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Taiwan Advance Bio-Pharmaceutical Inc. dividends
Taiwan Advance Bio-Pharmaceutical Inc. has not paid dividends in the last 7 fiscal years.
Who owns Taiwan Advance Bio-Pharmaceutical Inc.
Ownership data of Taiwan Advance Bio-Pharmaceutical Inc. is not available yet.
Taiwan Advance Bio-Pharmaceutical Inc. company profile
- Company name
- Taiwan Advance Bio-Pharmaceutical Inc.
- Ticker
- 4186.TWO
- ISIN
- TW0004186002
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 160
- Fiscal year end
- December
- Address
- No. 363, Section 2, Taipei, Taiwan
- Phone
- 886 2 2732 1999
- Website
- biotest.com.tw
About Taiwan Advance Bio-Pharmaceutical Inc.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA and rapid test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and polyclonal antibody products. It also offers stem cell banking services for newborn and adult stem cells storage; cell therapy programs; abused drugs rapid tests; operates drug testing center for urine drug test, hair drug test, and identification of drug abuse. The company also involves in research, development, production, and sales of veterinary drug residue testing reagents, drug abuse certification testing services and management, detection, extraction, cryopreservation and storage, and gene testing services for umbilical cord blood stem cells, umbilical cord mesenchymal stem cells, peripheral blood stem cells, and related businesses. Taiwan Advance Bio-Pharmaceutical Inc. was founded in 1989 and is based in Taipei, Taiwan.
Taiwan Advance Bio-Pharmaceutical Inc. management
1- Mr. Wen-Long SuPresident & Chairman of the Board